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LONG-TERM USAGE AND SIDE-EFFECT PROFILE OF 
SULPHASALAZINE IN RHEUMATOID ARTHRITIS
P. L. C. M. VAN RIEL, A. M. VAN GESTEL and L. B. A. VAN DE PUTTE
Department o f  Rheumatology, University Hospital Nijmegen, The Netherlands
SU M M A R Y
In a cohort o f patients with early rheumatoid arthritis, sulphasalazine (SASP) was mainly given as a first-choice second-line agent. 
SASP resulted in a significantly better survival rate compared with hydroxychloroquine, which is also given as a first-choice agent. 
When the survival rate o f  SASP was compared with that o f aurothioglucose, both given as second-choice agents, again, a 
statistically significant better survival rate was found for SASP. In 9% of the patients, SASP could be withdrawn as a complete 
remission was obtained. Adverse reactions occurred mainly during the first 3 months o f treatment, and in 20% o f patients these 
were severe enough to stop treatment. Gastrointestinal adverse reactions were most frequently observed, and all adverse reactions 
were completely reversible after treatment withdrawal. Treatment was started with a standard dose o f 2000 mg/day. However, 
in ~30%  of the patients, this dose was increased up to 3000 mg/day and, in another 30%, the dose was decreased to 1500 or 
1000 mg/day.
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Sulphasalazine (SASP), a conjugate of 5-aminosali-
cylic acid (5-ASA) and sulphapyridine, was synthesized 
in the 1940s as a drug to treat both rheumatoid arthritis 
(RA) and inflammatory bowel diseases [1]. As a result 
of conclusions based on a badly designed study, and 
the spectacular results of the use of corticosteroids in 
the treatment of RA, SASP fell out of favour for the 
treatment of RA and for many years was used mainly 
in the treatment of inflammatory bowel diseases [2]. In 
the late 1970s, the drug was rediscovered for the 
treatment of RA by McConkey et al. in the UK [3]. 
Since then, SASP is increasingly being used, particu­
larly in Europe, as a first-choice second-line agent for 
the treatment of RA. In this article, we will review our 
experiences with SASP in the treatment of RA over the 
last 10 yr.
PATIENTS AND METHODS
Since 1985, all patients with RA with a disease 
duration of <  1 yr, who have never been treated before 
with a second-line agent, have been included in a 
prospective cohort study. In general, treatment with 
second-line agents is considered if the disease is active 
despite treatment with non-steroidal anti-inflammatory 
drugs (NSAIDs) for 2 -4  weeks. During the early years 
of this cohort study, SASP and hydroxychloroquine 
(HQ) were agents of first choice. The choice of agent 
was dependent on the rheumatologist treating the 
disease. Since 1988, due to the results of the double­
blind trial comparing SASP with HQ, SASP was almost 
exclusively used as a first-choice second-line agent [4, 5]. 
The dosing schedule of SASP consists of a starting dose 
of 500 mg/day, which is increased weekly by 500 mg to 
the standard dose of 2000 mg/day. In cases of mild/
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moderate adverse reactions, the dose can be reduced to 
1500 or 1000 mg/day, and in cases of lack of efficacy, 
the dose is increased up to 3000 mg/day. To date, 240 
patients have been included in this cohort study.
Statistics
Kaplan-Meier product limit estimates of drug sur­
vival were used. The following endpoints were used: 
inefficacy, adverse drug reactions and treatment with­
drawal for different reasons (patient’s initiative, non- 
compliance, etc.). Data were censored to allow for 
patients lost to follow-up, death and drug withdrawal 
for remission. The log-rank test was used for compar­
ison of survival curves.
RESULTS
To date, 186 patients have been treated with SASP; 
in 76% of the patients, it was given as a first-choice, 
second-line agent. As a result, at the start of SASP 
treatment the median disease duration of the patients 
was only 1 yr and the radiographic damage was mini­
mal. The demographic data and clinical characteristics 
of these patients are shown in Table I.
The standard dose of SASP at the start of treatment 
was 2000 mg/day. However, as a result of adverse 
reactions and lack of efficacy in 32% of the patients, 
the dose was increased during the follow-up to 2500 or 
3000 mg/day, while in another 30% of patients the dose 
was decreased to 1500 or 1000 mg/day. About 50% of 
the patients in whom the dose was increased were still 
using SASP 20 months later (Fig. 1).
During the first 2 yr of SASP treatment, there was 
a gradual decrease in the drug survival curve due to 
drop-out because of lack of efficacy and toxicity. After 
2 yr, a flattening of the curve was observed (Fig. 2).
Following a comparison of patients who were 
treated with SASP as a first-choice second-line agent
(n 130) with 45 patients who were treated with HQ as
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TABLE I
Patient characteristics at baseline
Number 186
Sex (male: female) 122:64
Age (yr) 56 (19-86)*
Disease duration (yr) 1 (0 -7)*
RF positive (%) 84
Disease activity score 4.34 (1.38-7.15)*
Ritchie articular index 11 (0-47)*
ESR 40.5 (3-116)*
Radiographic damage 5 (0-79)*
SASP as first choice (%) 76
* Median (range).
RF, rheumatoid factor; ESR, erythrocyte sedimentation rate; 
SASP, sulphasalazine.
the first-choice agent, a statistically significant difference 
in favour of SASP was seen with respect to the drug 
survival in the first 2y r (P =  0.0001; Fig. 3). As it has 
been shown that the rank order of second-line agents 
influences drug survival, we also compared the survival 
of patients receiving SASP as a second-choice agent 
with patients who were treated with aurothioglucose as 
a second-choice agent [6], A statistically significant 
improvement in drug survival was seen in patients 
treated with SASP, mainly as a result of the high 
drop-out rate due to adverse reactions in the auro- 
thioglucose-treated group (P —  0.04; Fig. 4).
Withdrawals
In 47 patients, SASP had to be stopped due to 
adverse reactions. Gastrointestinal side-effects, such as 
nausea and vomiting, were most frequently observed, 
followed by adverse reactions, such as rash, fever and 
leucopenia (Table II). The majority of the withdrawals 
took place during the first 3 months of treatment and, 
after 1 yr, a plateau in the drug survival curve was 
observed (Fig. 5). Patients over 60 yr of age were more 
frequently withdrawn due to adverse reactions than 
patients under the age of 60 (P <  0.05).
In 17 patients, treatment could be stopped due to the 
absence of disease activity (‘remission’). During the 
follow-up period, eight patients had to start again with 
a second-line agent; in seven of these patients, SASP was 
re-instituted. Six patients responded again (one achieved 
a remission again) and one patient did not respond.
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Fig. 1.—Survival curve of sulphasalazine after dose increment.
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Fig. 2.—Survival curve of sulphasalazine in 240 patients with
rheumatoid arthritis.
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Fig. 3.—Survival curve of sulphasalazine compared with hydroxy­
chloroquine when given as first-choice disease-modifying anti­
rheumatic drug.
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Fig. 4. Survival curve of .sulphasalazine compared with tturo 
thioglucosc when given as second-choice, 
rheumatic drug.
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F ig. 5.— Survival curve o f sulphasalazine with adverse reactions as
the endpoint.
CONCLUSIONS
In this cohort of patients with early RA, SASP was 
given mainly as a first-choice second-line agent. The 
drug survival curve of SASP compared with HQ, both 
given as first-choice agents, was significantly better for 
SASP. After 2 yr, 50% of the patients on SASP and 
only 20% on HQ were still using the drug. The survival 
curve of SASP, if given as a second-choice agent, was 
also significantly better compared with that for auro- 
thioglucose. After 1 yr, 60% of those on SASP and 
40% on aurothioglucose were still receiving this 
treatment.
Adverse reactions severe enough to stop treatment 
occurred in ~20%  of the patients. All reactions were
reversible after stopping treatment; adverse reactions 
reappeared in only eight of the 17 patients in whom a 
rechallenge was performed.
The higher survival rates of SASP in this study are 
superior to those of Situnayake et al. [7]. One of the 
reasons for this discrepancy might be caused by the 
adjustment of the SASP dosage, as only about one- 
third of the patients were treated with the standard 
dose of 2000 mg/day.
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